BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jones BG, Hayden RT, Hurwitz JL. Inhibition of primary clinical isolates of human parainfluenza virus by DAS181 in cell culture and in a cotton rat model. Antiviral Res 2013;100:562-6. [PMID: 24076357 DOI: 10.1016/j.antiviral.2013.09.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Branche AR, Falsey AR. Parainfluenza Virus Infection. Semin Respir Crit Care Med 2016;37:538-54. [PMID: 27486735 DOI: 10.1055/s-0036-1584798] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 10.3] [Reference Citation Analysis]
2 Dhakal B, D'Souza A, Pasquini M, Saber W, Fenske TS, Moss RB, Drobyski WR, Hari P, Abidi MZ. DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation. Case Rep Med 2016;2016:8503275. [PMID: 26941799 DOI: 10.1155/2016/8503275] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
3 Waghmare A, Wagner T, Andrews R, Smith S, Kuypers J, Boeckh M, Moss R, Englund JA. Successful Treatment of Parainfluenza Virus Respiratory Tract Infection With DAS181 in 4 Immunocompromised Children. J Pediatric Infect Dis Soc 2015;4:114-8. [PMID: 26185620 DOI: 10.1093/jpids/piu039] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
4 Kumar N, Sharma S, Kumar R, Tripathi BN, Barua S, Ly H, Rouse BT. Host-Directed Antiviral Therapy. Clin Microbiol Rev 2020;33:e00168-19. [PMID: 32404434 DOI: 10.1128/CMR.00168-19] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
5 Chibanga VP, Dirr L, Guillon P, El-deeb IM, Bailly B, Thomson RJ, von Itzstein M. New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase. Antiviral Research 2019;167:89-97. [DOI: 10.1016/j.antiviral.2019.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
6 Salvatore M, Satlin MJ, Jacobs SE, Jenkins SG, Schuetz AN, Moss RB, Van Besien K, Shore T, Soave R. DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. Biol Blood Marrow Transplant 2016;22:965-70. [PMID: 26904972 DOI: 10.1016/j.bbmt.2016.02.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
7 McKimm-Breschkin JL, Fry AM. Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res 2016;129:21-38. [PMID: 26872862 DOI: 10.1016/j.antiviral.2016.01.012] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
8 Tharappel AM, Samrat SK, Li Z, Li H. Targeting Crucial Host Factors of SARS-CoV-2. ACS Infect Dis 2020;6:2844-65. [PMID: 33112126 DOI: 10.1021/acsinfecdis.0c00456] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]